Windward Bio Announces Pricing of Initial Public Offering

BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of $17.00 per share. In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below), without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be $225.0 million. All of the common shares are being offered by Windward.